TELA Bio Inc
NASDAQ:TELA
TELA Bio Inc
Research & Development
TELA Bio Inc
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
TELA Bio Inc
NASDAQ:TELA
|
Research & Development
-$9.1m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Haemonetics Corp
NYSE:HAE
|
Research & Development
-$62.2m
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-3%
|
|
|
ICU Medical Inc
NASDAQ:ICUI
|
Research & Development
-$87.5m
|
CAGR 3-Years
2%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-19%
|
|
|
Align Technology Inc
NASDAQ:ALGN
|
Research & Development
-$369.9m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-20%
|
|
|
Lantheus Holdings Inc
NASDAQ:LNTH
|
Research & Development
-$177.3m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-43%
|
CAGR 10-Years
-29%
|
|
|
Merit Medical Systems Inc
NASDAQ:MMSI
|
Research & Development
-$97.4m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-9%
|
|
TELA Bio Inc
Glance View
TELA Bio, Inc. is a commercial stage medical technology company, which focuses on the design, development, and market of tissue reinforcement materials. The company is headquartered in Malvern, Pennsylvania and currently employs 123 full-time employees. The company went IPO on 2019-11-08. The firm is focused on designing, developing and marketing tissue reinforcement materials for soft tissue reconstruction. The company offers a portfolio of products and solutions for care in hernia repair, abdominal wall reconstruction and plastic and reconstructive surgery. Its portfolio of products, the OviTex Reinforced Tissue Matrix (OviTex), is used for ventral hernia repair and abdominal wall reconstruction, inguinal hernia repair and hiatal hernia repair. Its OviTex PRS Reinforced Tissue Matrix (OviTex PRS) addresses needs in plastic and reconstructive surgery. Its OviTex PRS product is designed for use in implantation to reinforce soft tissue where weakness exists in patients requiring soft tissue repair or reinforcement in plastic and reconstructive surgery. Its subsidiary include TELA Bio Limited.
See Also
What is TELA Bio Inc's Research & Development?
Research & Development
-9.1m
USD
Based on the financial report for Sep 30, 2025, TELA Bio Inc's Research & Development amounts to -9.1m USD.
What is TELA Bio Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-18%
Over the last year, the Research & Development growth was 4%. The average annual Research & Development growth rates for TELA Bio Inc have been -5% over the past three years , -18% over the past five years .
